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Background: Comprehensive information on the incidence and duration of hepatitis C virus (HCV) infection for
people who inject drugs (PWID) in Ireland is not available. We created an incidence curve of injecting drug use in
Ireland and subsequently estimated incidence of hepatitis C virus (HCV) infection.
Methods: Anonymised data from the National Drug Treatment Reporting System (NDTRS) were used to identify all
people who inject drugs (PWIDs) and who entered drug treatment for the first time between 1991 and 2014. A
curve, estimating the incidence of injecting, was created to plot PWIDs by year of commencing injecting. The curve
was adjusted for missing data on PWIDs in treatment and for PWIDs who were never treated. An adjustment was
made to account for injectors who had never shared injecting equipment. The incidence of HCV infection and
chronic infection in PWIDs was estimated by applying published rates.
Results: Between 1991 and 2014, 14,320 injectors were registered on NDTRS. The majority were young (median
age 25 years), male (74%), lived in Dublin (73%) and injected an opiate (e.g. heroin) (94%). The estimated total
number of injectors up to the end of 2014 was 16,382. An estimated 12,423 (95% CI 10,799-13,161) were infected
with HCV, and 9,317 (95% CI 8,022-9,996) became chronically infected. The estimated annual number of new HCV
infections among PWIDs increased steeply from the late 1970s and peaked in 1998. By 2014, almost 30% of
injectors were estimated to have been infected for over 20 years.
Conclusions: This is the first comprehensive national estimate of the incidence of HCV in PWIDs in Ireland and will
inform planning and developing appropriate health care services.
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Hepatitis C (HCV) was first identified in 1989. The
acute phase of infection is usually asymptomatic, but
approximately 75% of those who are infected develop
chronic infection, which can cause liver cirrhosis, hepa-
tocellular carcinoma (HCC) and liver failure [1, 2]. The
risk of developing cirrhosis or HCC is higher in males,
those who consume excess alcohol, those with hepatitis
B or HIV co-infection [1] and those who were infected
at older ages [2]. Between 5 and 20% of those who are
chronically infected will develop cirrhosis after approxi-
mately 20 years of infection. Of those with cirrhosis, ap-
proximately 4% progress to decompensated liver disease
each year and 1.6% develop HCC annually [2].* Correspondence: lelia.thornton@hse.ie
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(http://creativecommons.org/publicdomain/zeThe main modes of transmission of HCV infection in
Ireland are injecting drug use and the receipt of contam-
inated blood or blood products before the introduction
of routine screening for HCV in the early 1990s. Infor-
mation on the epidemiology of HCV in Ireland is mostly
available from National Virus Reference Laboratory
(NVRL) data since 1989, routine surveillance data based
on statutory laboratory and clinical notifications to the
Health Protection Surveillance Centre (HPSC) since
2004, and special studies in high prevalence groups such
as people who inject drugs (PWIDs) and prisoners.
A study using NVRL diagnostic data and HPSC notifi-
cation data estimated that approximately 10,000 individ-
uals had been diagnosed with HCV and were living with
chronic infection in Ireland by the end of 2009 [3]. The
extent of underdiagnosis in Ireland is not known, but as-
suming levels of between 50 and 67% would increasele is distributed under the terms of the Creative Commons Attribution 4.0
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[4]. Drug use was the most likely risk factor in 80% of
the cases of HCV diagnosed by the NVRL between 1989
and 2004, of which 53% were genotype 1 and 42% geno-
type 3 [3]. A further 4,813 cases of HCV were notified
to HPSC between 2010 and 2014 and, where risk factor
data were available, approximately 80% were PWIDs [5].
The most recent capture-recapture study found that
there were approximately 12,000 known opiate users
(ever-injectors and non-injectors) in Ireland in 2006 and
estimated the total number of known and ‘hidden’ opiate
users to be 20,790 (95% CI 18,136-23,576) [6, 7]. Testing
for blood-borne viral infections is offered to PWIDs in
Ireland when they first attend opiate substitution services
(clinics, prisons, and general practice) and is repeated at
regular intervals. An Irish opiate treatment outcomes
study commissioned in 2002 showed that HCV testing
was carried out for 82% of attendees entering treatment
services in rural, urban and inner-city areas [8]. However,
addiction treatment services were not widely available out-
side of Dublin until more recent years and the proportion
of PWIDs with undiagnosed HCV infection is likely to
be higher outside of Dublin. Studies of PWIDs in
prisons, opiate substitution services and general prac-
tice in Ireland, between 1992 and 2006, estimated the
HCV antibody prevalence in this population to be be-
tween 52 and 84% [9–17]. Using a weighted average of
the estimates from these studies (based on sample size),
the national prevalence of HCV in PWIDs was calcu-
lated to be approximately 70% [16]. More recently, a
cross-sectional study in 2011 reported lower levels of
HCV antibody positivity in the prison population, with
41.5% of those with a self-reported history of ever
injecting drugs testing positive for anti-HCV [18]. Of
note, the prevalence of HCV infection differed depend-
ing on the type of drug injected; for example, 54% (80/
149) of heroin injectors, 66% (66/100) of cocaine injec-
tors and 62% (42/68) of benzodiazepine injectors tested
HCV antibody positive, whereas only 21% (14/66) of
steroid injectors tested positive [19].
The incidence and duration of HCV infection in
Ireland have never been comprehensively described. The
aim of this study was to estimate the incidence of HCV
infection among PWIDs in Ireland. The objectives were:
(1) to create an incidence curve of injecting drug use, (2)
to estimate the annual incidence of HCV in PWIDs and
(3) to estimate the number of PWIDs who developed
chronic HCV infection.
Methods
Anonymised individualised data from the National Drug
Treatment Reporting System (NDTRS) formed the basis
of this study. The NDTRS records information on
treated problem drug use in Ireland using an agreedEurope-wide protocol (http://www.emcdda.europa.eu/
publications/manuals/tdi-protocol-3.0) and covers 76%
of drug and alcohol treatment services in Ireland. It was
established in the Greater Dublin Area in 1990 by the
Health Research Board and was extended in 1995 to
cover all areas of the country [20]. Treatment data for
problem drug use in Ireland are provided to the NDTRS
by statutory and non-statutory services, including out-
patient services, residential centres and general practices.
Clients who attend needle-exchange services are not in-
cluded in this reporting system. The database records
client information on the date of treatment, whether a
client has ever previously received drug treatment (inci-
dent case identifier), ever injected drugs, age when they
first injected, and recent injection behaviour, in addition
to detailed demographic, drug use and treatment data.
The NDTRS does not contain information on HCV status.
Injecting and HCV infection curves were created using
a four-stage process.
1. Original injector data and imputed missing values
In 2016, all ever-injector individuals, whether current
or former injectors, entering drug treatment for the
first time between 1991 and 2014 were identified and
extracted from the NDTRS. The length of time an
individual injected before coming to their first
treatment as an injector was ascertained and an
injecting curve was created for the number of cases
starting to inject each year. The year of commencing
injecting was missing for a proportion of cases.
Factors associated with missing values were
investigated and discovered not to be completely
random. Therefore, in order to account for this,
missing data were generated using Expectation-
Maximization (EM) methods. The original and
imputed data were combined to create an
epidemic curve based on the year of commencing
injecting for all PWIDs registered on the NDTRS
up to the end of 2014.
2. Estimating injectors not in treatment
Treated PWIDs represent a proportion of the
injecting drug population. Estimates for the
proportion of PWIDs not in treatment were used to
adjust the epidemic curve for all PWIDs. In the
absence of Irish data for this proportion, Scottish
rates were applied to each yearly estimate of
injectors residing in Dublin (6% of injectors never
attended treatment in Glasgow between 2008 and
2010) [21]). Scottish data were considered the most
appropriate as the drug situation in Dublin has been
likened to that in Glasgow [22]. For injectors living
outside Dublin, a worst case scenario estimate of
50% non-attendance was used based on the 2006
capture-recapture estimate [7], as appropriate harm
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available to a large proportion of these. No adjustment
was made to take account of PWIDs who died prior
to the commencement of the NDTRS in 1991. Using
a Mann–Whitney U test, the estimated number of
injectors was validated by comparing it with published
data available for four time points, from capture
recapture studies estimating the number of opiate
users in Ireland [6, 7]. The number of opiate users
who were injectors was derived using the known
percentage of opiate injectors in the NDTRS.
3. Estimating HCV infections
In order to adjust for injectors who were not at risk
of infection a conservative 21% deduction was made
from the total estimate of injectors to allow for
those who had never shared injecting equipment.
The 21% was based on the lowest annual proportion
of cases (worst case scenario) who reported through
the NDTRS that they had never shared and had
been in treatment for drug use two or more times
during the 23 year time period [unpublished NDTRS
data]. In order to estimate the incidence of HCV
infection among PWIDs, published HCV incidence
rates in PWID populations for different time periods
in Ireland were applied to the injecting curve.
Incidence data were available for two time periods.
Smyth et al. found a HCV incidence rate of 66 per
100 person years (95% CI 51–84) in a study carried
out between 1992 and 1998 [23]. This rate and its
95% confidence intervals (CI) were used for those
who commenced injecting between 1992 and 1998.
In a study carried out in 2001, Grogan et al. [13]
estimated that the infection rate for clients in opiate
substitution services in the parts of Dublin and
surrounding areas was 24 per 100 person years (95%
CI 12.2–43.8) but included both injectors and non-
injectors in their denominator. We adjusted this rate
and its 95% confidence intervals using the proportion
of opiate users entering treatment in the area in 2001
who were recorded in the NDTRS as having reported
injecting (70%) and thus estimated the infection rate
in PWIDs to be 35 per 100 person years (95% CI
17.4–62.6). This rate and its 95% confidence intervals
were applied to 2001 and continued for the period
2001 to 2014 as these were the most recent estimates.
As no published data were available for the period
1953 to 1991, the mid-point between the highest and
lowest incidence and its confidence intervals for the
two periods with known incidence rates were applied;
these were a rate of 50.7 per 100 person years and
95% CI of 17.4–84. For 1999 and 2000 the mid-points
of the rate and the upper and lower confidence
intervals for the two periods with known
incidence rates on either side of the timeline wereapplied (50 per 100 person years, and 95% CI
34.6–73.4).
4. Estimating chronic HCV
In order to obtain an estimate of chronic HCV
infections, an internationally accepted 75% conversion
from acute to chronic HCV was applied to the HCV
infections curve [2].
Results
Original injector data and imputed missing values
During the 23-year study period (1991–2014), 14,320
ever-injectors entered addiction treatment and were reg-
istered on the NDTRS. The majority were male (74.3%)
and lived in Dublin (73.0%). The median age for injec-
tors entering treatment was 25 years (90% central range
18–40 years) while the median age at commencing
injecting was 20 years (90% central range 15–31 years).
Half of all PWIDs had injected for 3 years or more
before entering addiction treatment (90% central range
0–18 years). Opiates were the main problem drug
reported by 94.1% of PWIDs. Seventy one per cent
reported problem use of more than one drug and 14.7%
had been in treatment as a smoker and later returned to
treatment as an injector. Problem alcohol use was
reported by 9.1% of injectors on entering treatment.
Data necessary to calculate the year of first injecting
were available for 86.4% (n = 12,375) and missing for
13.6% (n = 1,945). The most common missing informa-
tion was age first injected (n = 1,929, 13.5%). Using logis-
tic regression, year of treatment and main problem drug
were found to be significantly associated with the prob-
ability of a patient’s record not having data on age first
injected. An imputed year of first injecting was assigned
to individuals with missing data using the pattern of
observed data for similar injectors (Fig. 1).
The resulting injecting curve shows few new PWIDs
in Ireland prior to 1970 (n = 36, 1957 to 1969); the esti-
mated number of new PWIDs increased steadily in the
late 1970s and then continued to increase at a lower rate
into the 1980s (Fig. 1). Incidence of injecting increased
again in the late 1980s and early 1990s, peaking in 1998.
Data from 2011 to 2014 are likely to be incomplete due
to the lag time between injecting and first attending
treatment.
Estimating injectors not in treatment
Adjusting for PWIDs who had never attended drug
treatment services and therefore who were not regis-
tered on the NDTRS, added a further 2,062 injectors to
the curve. The total estimated number of PWIDs up to
the end of 2014 is 16,382 (Fig. 1).
Estimates from the injecting curve were validated
against the number of opiate injectors estimated using



























Original NDTRS injector data Original NDTRS injector data plus imputed missing values All injectors (NDTRS and non-NDTRS)
Fig. 1 New injectors by year of commencing injecting
Carew et al. Hepatology, Medicine and Policy  (2017) 2:7 Page 4 of 7over four different years [6, 7] and data on the percent-
age of opiate users who were injecting in those years
from the NDTRS (Table 1). Overall the estimates were
not statistically significantly different (U = 5.00, p = 0.49).
Estimated HCV infections
After adjusting for injectors who had never shared
injecting equipment, it is estimated that 12,423 (95% CI
10,799-13,161) PWIDs were infected with HCV over the
entire period (Fig. 2) and that 9,317 (95% CI 8,022-9,996)
became chronically infected (Fig. 3). The estimated num-
ber of new infections peaked in 1997. By 2014, more than
one quarter (27.0%) of PWIDs with chronic HCV infec-
tion were estimated to have been infected for 0–10 years,
43.4% for 11–20 years, 22.8% for 21–30 years and 6.7% for
over 30 years.
Discussion
This study is the first comprehensive national estimate
of the incidence of injecting drug use in Ireland along
with the incidence and extent of the hepatitis C epi-
demic in this population. Results show an estimatedTable 1 Comparison of estimates from the injecting curve with pub
Year Opiate users in
capture recapturea

















a[6, 7]16,400 PWIDs in Ireland during the 24 year study period
(1991–2014). The majority of injectors were young,
male, lived in Dublin and injected heroin. Over 12,000
PWIDs were estimated to have been infected with HCV
by 2014, with over 9,000 likely to have become chronic-
ally infected. More than 40% of injectors were estimated
to have been infected for 11–20 years by 2014 and al-
most 30% were estimated to have been infected for over
20 years. However, some of these injectors will have
since died or may have been successfully treated for
HCV infection and the cumulative incidence numbers
presented in this paper do not take account of these
events. In relation to deaths, the National Drug-Related
Death Index reported that 937 PWID who were hepatitis
C-infected died between the years 1998 and 2014 (Per-
sonal communication: Dr Suzi Lyons, Senior Researcher,
National Health Information Systems, Health Research
Board. 8 November 2016). In relation to treatment for
hepatitis C, a national programme set up at the end of
2014 offering direct acting antivirals to individuals test-
ing positive for hepatitis C and meeting pre-defined clin-
ical criteria reported that 138 PWID were successfullylished data from a capture recapture study
jectors Opiate injectors calculated
from injecting curve
% difference between capture























All injectors (NDTRS and non-NDTRS) Estimated new HCV infections Lower bound new HCV infections Upper bound new HCV infections
Fig. 2 Estimates of new injectors by year commenced injecting and new HCV infections by year infected
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between December 2014 and August 2016 (Personal
communication: Michele Tait, Programme Manager,
HSE Hepatitis C Treatment Programme. 3 November
2016). Prior to this, research published in 2007 indicated
that few PWID were suitable for (13%) or commenced
(3%) antiviral treatment [15]. Thus the overall numbers
successfully treated or who died are likely to be small
and do not change the overall estimate of the extent of
the hepatitis C epidemic.
The overall size and pattern of the estimated hepatitis
C incidence curve is similar to a hepatitis C infection
curve based on the date of laboratory diagnoses, despite
a different study approach [3]. Both studies found that
hepatitis C incidence is now decreasing in Ireland. This



















All injectors (NDTRS and non-NDTRS) Estimated chronic HCV infections
Fig. 3 Estimates of new injectors by year commenced and chronic HCV inthat statutory notifications have declined significantly
since 2012 [5]. Given this fall in the number of newly
diagnosed cases and the fact that the most recent inci-
dence study dates to 2001, the authors acknowledge that
there may be a corresponding overestimate in later
years. As PWIDs make up the majority of known hepa-
titis C infected people in Ireland, the results from this
study are of benefit in estimating the extent of the over-
all HCV epidemic in Ireland. The other known large
cohort is people infected through blood and blood prod-
ucts in the past in Ireland. This is a historical cohort of
over 1,700 people, approximately 390 of whom remained
alive and chronically infected at the end of 2013 [24].
Undiagnosed infection in this population would be
expected to be rare due to extensive national screening
programmes. There may, however, be a significant85 1995 2005 2015
 
Lower bound chronic HCV infections Upper bound chronic HCV infections
fections by year infected
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grant population in Ireland. Although asylum seekers
are routinely offered infectious disease screening, there
is no systematic testing for other migrants. At the time
of the 2011 census, there were 766,770 non-Irish na-
tionals living in Ireland. Based on census data on the
number of people living in Ireland by country of birth
(CSO unpublished data, Olive Pluck, CSO) and pub-
lished data on the prevalence of anti-HCV by country of
birth [25, 26], over 10,000 of these are likely to be
chronically infected with HCV. This assumes that the
prevalence of HCV in the migrant population in Ireland
is similar to published data for the general population in
their country of birth.
There are a number of limitations to the methods used
in this study. The number of PWIDs who never accessed
drug treatment was unknown and was estimated. How-
ever, the estimates of PWIDs were validated against cap-
ture recapture studies [6, 7] and were not statistically
different. The hepatitis C infection rates that were applied
were based on incidence studies during two specific time
periods and varied considerably from 66 to 35%. This is
not surprising as HCV incidence rates for Glasgow show
similar variations although their injecting curve is approxi-
mately 10 years ahead of the Irish curve; for example,
model-based rates estimated for Glasgow were 6–40,
78–89 and 18–30 per 100 injector-years during the
periods 1960–1976, 1977–1986 and 1990–2000 re-
spectively [27]. The decrease in the incidence of HCV
infection in opiate users in Ireland may be due to the
provision of opiate detoxification and substitution in
prisons and the increased provision of such programmes
in the community, in particular outside Dublin [28]. An-
other limitation was that we did not have data on whether
individuals ceased to inject. Therefore HCV infection rates
were applied to each individual each year. However, a pro-
portion of individuals may have ceased injecting prior to
becoming HCV infected and no longer have been at risk
of infection. A proportion of individuals may also have
died, and this is not reflected in the estimates described
here. Our interval estimates in Figs. 2 and 3 account for
known uncertainties in the inputs, but do not account for
other uncertainties and modelling assumptions the impact
of which is not explicitly known. Despite these limitations,
as already stated, modelled curves are broadly in line with
those described by laboratory diagnoses and by surveil-
lance data [3, 5].
Modelling the progression of disease for the population
is of interest from a public health perspective, especially in
the context of emerging treatments for HCV. This
work is ongoing by one of the authors (CW), involving
the calibration of disease models, and evidence synthe-
ses for treatments that are available, and is due for
publication in the near future. The additive effect ofalcohol use on progression of HCV-related cirrhosis [1]
will be an important factor to take into account, as
PWIDs in Ireland have been shown to have a high
prevalence of problem alcohol consumption. Only 9%
reported problem alcohol use on first entry to treat-
ment; however, data on previously treated opiate users
indicate that 21% reported problem alcohol use [18]
and 35% of opiate users receiving methadone in general
practice in Dublin were harmful alcohol users [29].
Recent drug treatment data show that the number of
injectors entering drug treatment for the first time in
Ireland has dropped slightly in recent years [30]. How-
ever, injecting drug use remains a significant issue. The
European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) recommends the collection of
accurate data on the incidence of injectors entering
treatment as this is an indicator of problem drug use
[31]. Therefore, this analysis demonstrates the wider
usefulness of routine drug treatment data collected by
the NDTRS. It is important that harm reduction strat-
egies continue to be implemented and evaluated in
order to achieve reductions in injecting risk behaviours
and HCV transmission. Although the incidence of
injecting and the incidence of HCV have declined in
recent years, unless substantial numbers receive treat-
ment for their HCV infection the burden of HCV-
related liver complications will be high over the next
few decades. The information from this study will be of
benefit in planning cost-effective approaches to the use
of the highly effective but expensive direct acting anti-
viral treatments now available.Conclusions
This paper is the first comprehensive national estimate
of the incidence of injecting drug use in Ireland, along
with the incidence and extent of the hepatitis C
epidemic in this population. The findings will inform
those responsible for planning and developing health
care services and will be of benefit in planning cost-
effective approaches to the use of the highly effective but
expensive new treatments for hepatitis C that have re-
cently become available.Additional file
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